Evidence map›Paper›PMID 39554156›Full record

ArticlebioRxiv : the preprint server for biology2024

Transcriptional phenotype of the anti-parasitic benzodiazepine meclonazepam on the blood fluke

Clair R Henthorn, Paul McCusker, Winka Le Clec'h, Frédéric D Chevalier, Timothy J C Anderson, Mostafa Zamanian, John D Chan

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Clair R HenthornDepartment of Pathobiological Sciences, University of Wisconsin - Madison, Madison, WI, USA.
Paul McCuskerDepartment of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.
Winka Le Clec'hHost-Pathogen Interactions program, Texas Biomedical Research Institute, San Antonio, TX, USA.
Frédéric D ChevalierHost-Pathogen Interactions program, Texas Biomedical Research Institute, San Antonio, TX, USA.ORCID 0000-0003-2611-8106
Timothy J C AndersonDisease Intervention and Prevention program, Texas Biomedical Research Institute, San Antonio, TX, USA.ORCID 0000-0002-0191-0204
Mostafa ZamanianDepartment of Pathobiological Sciences, University of Wisconsin - Madison, Madison, WI, USA.ORCID 0000-0001-9233-1760
John D ChanDepartment of Pathobiological Sciences, University of Wisconsin - Madison, Madison, WI, USA.ORCID 0000-0003-4986-972X

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Parasitology and Vector Biology Training ProgramT32AI007414 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI Lyric Colleen Bartholomay · 1992 to 2026
$4.5M
Genetic Basis of Praziquantel ResistanceR01AI123434 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J, LOVERDE, PHILIP T · 2016 to 2020
$3.5M
Genetic analysis of cercarial release in schistosomesR01AI133749 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2017 to 2021
$2.5M
Molecular mechanisms controlling secretion in filarial nematode parasitesR01AI151171 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI Mostafa Zamanian · 2020 to 2026
$2.4M
Discovery of new molecular phenotypes for anti-schistosomal drug screeningR21AI153545 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI CHAN, JOHN D, ZAMANIAN, MOSTAFA · 2020 to 2021
$415k
Development of non-sedative, parasite-selective benzodiazepines to treat the neglected tropical disease schistosomiasisR21AI146540 · NIAID · UNIVERSITY OF WISCONSIN OSHKOSH · PI CHAN, JOHN D · 2020 to 2021
$405k
MOLECULAR AND BIOCHEMICAL GENETICS LABORATORY RENOVATIONC06RR013556 · NCRR · SOUTHWEST FOUNDATION FOR BIOMEDICAL RES · PI SHADE, ROBERT E · 1998 to 1998
–
NCRR NIH HHS C06 RR013556NIAID NIH HHS HHSN272201700014CNIAID NIH HHS R01 AI123434NIAID NIH HHS R01 AI133749NIAID NIH HHS R01 AI151171NIAID NIH HHS R21 AI146540NIAID NIH HHS T32 AI007414NIH HHS P51 OD011133
6 · The paper itself

Abstract

There are limited control measures for the disease schistosomiasis, despite the fact that infection with parasitic blood flukes affects hundreds of millions of people worldwide. The current treatment, praziquantel, has been in use since the 1980's and there is a concern that drug resistance may emerge with continued monotherapy. Given the need for additional antischistosomal drugs, we have re-visited an old lead, meclonazepam. In comparison to praziquantel, there has been relatively little work on its antiparasitic mechanism. Recent findings indicate that praziquantel and meclonazepam act through distinct receptors, making benzodiazepines a promising chemical series for further exploration. Previous work has profiled the transcriptional changes evoked by praziquantel treatment. Here, we examine in detail schistosome phenotypes evoked by

Identifiers

PMID39554156
PMCPMC11565718

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.